Protocol for Researching the RAD-140 / S-23 / LGD-4033 Stack:
RAD-140 – For research use only, 1 filled oral syringe daily. RAD-140 can be researched for up to 4 weeks.
S23 – For research use only, 1 filled oral syringe daily. S23 can be researched for up to 8 weeks.
LGD-4033 – For research use only, 1 filled oral syringe daily. LGD-4033 can be researched for up to 8 weeks. After completion of a cycle, there should be an 8-week break before resuming research.
PCT – After the cycle is completed, Nolva or Clomid should be used for PCT, at 1 oral syringe per day for 30 days.
RAD-140
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
RAD140 is an investigational selective androgen receptor modulator (SARM) that is developed by Radius Health, Inc. for use in androgen replacement therapy. It was licensed to Ellipses Pharmaceuticals in 2020. Some of the potential benefits under investigation are for the treatment of conditions such as muscle wasting and bone loss.
S23
S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.
LGD-4033
According to a clinical trial conducted at the Boston Medical Center’s Section of Endocrinology, Ligandrol can help improve lean body mass and muscle strength.
Another study conducted in January 2013 found that Ligandrol can help increase lean muscle mass, and was generally well tolerated by test subjects.
